Ashburn, Virginia — October 10, 2025 — Leads & Copy — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has announced a securities purchase agreement with healthcare-focused institutional investors, potentially raising up to $104.5 million.
The financing includes $16.5 million in upfront funding and an additional $88.0 million upon the exercise of accompanying warrants. The private placement was priced at a premium to the company’s prior day’s closing stock price.
Investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, are participating in the financing.
Quoin will issue 1,993,940 American Depository Shares (ADSs) and warrants to purchase up to 7,975,760 ADSs at $8.25 per ADS and accompanying warrants. The warrants consist of four tranches with varying exercise prices and expiration dates.
The company plans to use the proceeds for general corporate purposes, including research and development for QRX003 for Netherton Syndrome. The aggregate net proceeds are expected to fund the company into 2027.
Maxim Group LLC acted as the sole placement agent for the private placement.
The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and may not be reoffered or resold in the United States without registration or an applicable exemption. The company has agreed to file a registration statement with the SEC for the resale of the ADS purchased in the private placement and the ADS underlying the warrants.
Michael Myers, Ph.D., CEO, mmyers@quoinpharma.com
Jeff Ramson, PCG Advisory, jramson@pcgadvisory.com, (646) 863-6341
Source: Quoin Pharmaceuticals Ltd.
